Veradermics (MANE) Change in Accured Expenses (2025 - 2026)

Veradermics posted quarterly Change in Accured Expenses of -$8000.0 for Q1 2026, down 14.29% year-on-year from -$9333.3 in Q1 2025, and down 14.29% on a QoQ basis from -$7000.0 in Q1 2025.

Veradermics (MANE) has 2 years of Change in Accured Expenses data on file, last reported at -$8000.0 in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - 931,000.00
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 70.50 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 107.70 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -176.03 Mn
10 Veradermics 2.29 Bn 2.29 Bn - -8,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -8,000.00
Mar 31, 2026 -8,000.00
Mar 31, 2025 -7,000.00
Mar 31, 2025 -7,000.00